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Abstract
Introduction: The critical role of bacteria in the pathogenesis of ulcerative colitis (UC) is well recognized, but an individual
causative microorganism has not been singled out so far. Campylobacter concisus and other non-jejuni species of
Campylobacter have been implicated as putative aetiological agents in inflammatory bowel disease in children, but such
studies have not been addressed in adults. This study investigated the prevalence of Campylobacter species in colonic
biopsy samples from adults with UC and healthy controls.
Methods: Adult patients who were undergoing diagnostic colonoscopy were recruited for the study, which included 69
patients with histologically proven UC and 65 healthy controls. DNA was extracted from the biopsy samples and subjected
to Campylobacter genus specific and Campylobacter concisus specific polymerase chain reaction and sequencing.
Results: Detection of all Campylobacter DNA utilising genus specific primers was significantly higher in cases of UC, with a
prevalence of 73.9% (51/69) compared to 23.1% (15/65) in controls (p = 0.0001). Nested PCR for C. concisusDNAwas positive in
33.3% (23/69) of biopsy samples from subjects with UC, which was significantly higher than the prevalence rate of 10.8% (7/65)
from controls (p = 0.0019). Sequencing of the remaining Campylobacter positive samples revealed that Campylobacter
ureolyticuswas positive in 21.7% (15/69) of samples from UC subjects as opposed to 3.1% (2/65) in controls (p = 0.0013). Mixed
Campylobacter species were more common in UC patients, 20.3% (14/69) as compared to controls 4.6% (3/65) (p = 0.0084).
Conclusion: The higher prevalence of Campylobacter genus and more specifically C. concisus and C. ureolyticus in biopsy
samples from adults with UC suggests these genera of bacteria may be involved in the chronic inflammation that is
characteristically seen in UC. To the best of our knowledge this is the first report of this association of C. concisus and C.
ureolyticus with UC in adults.
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Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic
diseases of the gastrointestinal tract that together are usually
referred to as inflammatory bowel disease (IBD). During the last
two decades there has been a significant increase in IBD associated
hospitalization, outlining the enormous economic impact to health
services [1]. It has been projected that at anytime up to 240,000
people are affected by IBD in the UK [2]. More specifically, the
epidemiological pattern of UC has changed significantly with an
increased incidence estimated at 10–20 per 100 000 per year. The
incidence rate of juvenile onset UC has also risen in Scotland over
the last twenty years, which translates into a longer period of
monitored healthcare for affected individuals [3,4,5].
Ulcerative colitis has been traditionally observed in developed
societies but with increasing westernization its prevalence has been
on the rise in developing countries as well [6,7]. The current
paradigm of the pathogenesis of UC revolves around an aberrant
host immune response that is triggered by a poorly understood
interaction between the microbiome and host genetic defects
involved in the identification and clearance of microbes [8]. The
genetic associations with UC are not as strong as CD suggesting a
greater role of luminal factors influencing its pathogenesis. It is
postulated that ‘dysbiosis’ or an imbalance between protective and
harmful components of the luminal microbiota in favour of the
latter plays a critical role in initiating and possibly perpetuating
inflammation in UC [9].
Recent methodological advances in studying the gut micro-
biome have made clear distinctions between the mucosa-
associated and faecal populations [10,11]. It is suggested that in
healthy individuals the mucosal microbiome forms a synergistic
and stable interaction with the host immune system, while the
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luminal or faecal microbiome varies based on diet or other
environmental factors. This distinction is critical as it is therefore
more likely that mucosa-associated bacteria will have the ability
and proximity to invade the protective mucous layer and the
intestinal epithelial barrier. Helicobacter and Bacteroides species are
two groups of mucosa-associated bacteria that have been
implicated in the pathogenesis of UC [12,13,14]. A recent
epidemiological study demonstrated an increased risk of IBD in
individuals with an episode of Campylobacter or Salmonella
gastroenteritis, suggesting that infection with particular bacteria
may trigger the process that ultimately leads to the chronic
inflammation of IBD [15]. Other population-based studies have
however refuted these findings and suggested that this association
is perhaps a result of detection bias [16]. More recently, the role of
non-jejuni Campylobacter species have evoked attention, predomi-
nantly in paediatric Crohn’s disease [17,18].
The members of the Campylobacter genus comprise Gram
negative, spiral, microaerophilic bacteria that reside in the small
or large intestine of humans and animals. At least a dozen species
of Campylobacter have been associated with human disease, with
Campylobacter jejuni and Campylobacter coli the most commonly
isolated strains. However, newer information suggests that non-
jejuni Campylobacter species, most specifically Campylobacter concisus,
may be responsible for infective gastroenteritis and septicaemia in
children [19]. This species has also been isolated from stool
samples of immunocompromised patients with diarrhoea suggest-
ing that it may even be an opportunistic pathogen [20]. The recent
reclassification of Campylobacter ureolyticus has added another species
in the broader genus of Campylobacter having previously been within
the Bacteroides [21]. The identification of this species in the faeces of
subjects presenting with gastroenteritis suggests that it may also be
an emerging enteric pathogen [22]. It appears that non-jejuni
Campylobacter species are increasingly being identified as potential
gastrointestinal pathogens. This study has for the first time aimed
to delineate these mucosa-associated bacteria in biopsy samples
from adults with ulcerative colitis.
Methods
Study Subjects
Patients were recruited from the department of gastroenterology
at Aberdeen Royal Infirmary. These subjects were recruited for a
previous study looking at the role of enterohepatic Helicobacter in
UC [14]. Sixty-nine patients with a primary diagnosis of UC on
the basis of a histological diagnosis from colonoscopic biopsies
were recruited and assessed. The extent and severity of disease was
scored according to the Montreal criteria [23]. A total of sixty-five
healthy controls were recruited from the bowel cancer screening
programme if they had documented absence of both macroscopic
and microscopic inflammation. Subjects were excluded if they
received antibiotics within six months prior to recruitment.
Colonic biopsies were obtained from colonoscopy procedures
carried out at Aberdeen Royal Infirmary, Aberdeen, UK. Ethical
approval for the study was granted by the North of Scotland
Research Ethics Service, UK (reference number 04/S0802/8).
Written informed consent was obtained from all subjects in the
study.
Biopsy collection, Processing and Genomic DNA
Extraction
Biopsy samples were collected from patients with UC and
controls during colonoscopy using standard endoscopic forceps
(Boston Scientific Nanterre Cedex France). The colonic mucosa
was washed with sterile water via the colonoscope to remove
residual faecal material. Biopsies were immediately snap-frozen in
liquid nitrogen and then transferred to a -80uC freezer for storage
pending DNA extraction and analysis.
Genomic DNA was extracted from the biopsies using the
QIAamp DNA Mini Kit (Qiagen, Crawley, UK) according to an
established modification of the manufacturer’s instructions,
optimised in-house for colonic biopsy tissue [14]. Biopsy samples
were kept frozen until the addition of ATL buffer, thereafter they
were allowed to equilibrate to room temperature. An additional
10 ml of Proteinase K was added for an initial lysis period of
18 hours to ensure complete lysis of the biopsy material prior to
DNA extraction. DNA obtained from the biopsy samples was
initially subjected to universal bacterial PCR to confirm the
suitability of the DNA for further analysis [24].
PCR amplification
Campylobacter genus specific PCR. The Campylobacter
genus-specific primers, C412F and C1228 R, described by
Linton et al in 1996 were used to amplify a <800 bp fragment
within the 16S rRNA gene of Campylobacter species [25].
Campylobacter DNA was detected in the extracted biopsy samples
by PCR using a 50 ml reaction mixture consisting of 10 pmol of
each primer (C412F and C1228R [Sigma-Aldrich, UK]), 16PCR
buffer (Roche, UK), 250 nM of each deoxy-nucleotide-
triphosphate (Bioline, UK), 2 mM MgCl2 (Roche, UK), 1 U of
Taq polymerase (Roche,UK), and 40 ng of DNA. The PCR
cycling conditions used were: 30 cycles of 94uC for 30 seconds,
55uC for 30 seconds, and 72uC for 2 minutes.
Campylobacter concisus specific PCR. C. concisus specific
primers, Concisus F and Concisus R, were used to amplify a
560 bp fragment within the 16S rRNA gene of C. concisus strains as
per the protocol described by Ming Man et al in 2010 [18]. The
sequences corresponding to the primer pair Concisus F/Concisus
R were located within the region amplified by the Campylobacter
genus specific primer C412F and C1228R and hence a nested
PCR approach was used to identify the C. concisus strains -
Campylobacter genus-specific PCR was therefore followed by C.
concisus specific PCR. The composition of a 50 ml PCR reaction
mixture was: 10 pmol of each primer (Concisus F and Concisus R
[Sigma-Aldrich, UK]), 16 PCR buffer (Roche, UK), 250 nM of
each deoxy-nucleotide-triphosphate (Bioline, UK), 2 mM MgCl2
(Roche, UK) and 1 U of Taq polymerase (Roche, UK). The
optimum thermal cycling conditions for the C. concisus-specific
nested PCR were: 94uC for 5 minutes, 40 cycles of 94uC for
30 seconds, 65uC for 30 seconds, and 72uC for 1 minute, followed
by 72uC for 7 minutes.
Cloning and Sequencing
To enable the identification of other Campylobacter species,
Campylobacter genus positive PCR products were first subjected to
restriction fragment length polymorphism (RFLP) analysis by
digestion with Dde I enzyme [26]. PCR products which did not
show a mixed RFLP pattern were directly sequenced on an Applied
Biosystems model 3730 automated capillary DNA sequencer using
the Campylobacter genus specific primers C412F and C1228R.
Samples with mixed RFLP profiles were analyzed by cloning the
Campylobacter genus positive PCR products into JM109 competent
cells with pGEM-T-easy vector and the sequence of the insert was
established with M13 sequencing primers.
The sequences obtained were compared to those of the National
Center for Biotechnology Information GenBank database using
the basic local alignment search tool (BLAST) search program
(http://www.ncbi.nlm.nih.gov).
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Multiple alignments and phylogenetic analyses were performed
using Bioedit (version 7.0.5.3) (http://www.mbio.ncsu.edu/BioE-
dit/bioedit.html) and a dendogram was constructed using MEGA
version 4 software [27].
GenBank Sequence Submission
All 16S rRNA gene sequences derived from either direct
sequencing or cloning of Campylobacter genus-specific PCR
products were submitted to GenBank with the accession numbers
from JF795865 to JF795912.
Statistical Analysis
Statistical analysis was performed using the Pearson Chi
Squared, 2-tailed test or the Fisher’s exact test wherever
appropriate, utilising Graph Pad software (San Diego, CA).
Results
Patient characteristics
The prospective UC cohort (n = 69, male 46.4%) had a mean
age of 45.3617.9 years at the time of index colonoscopy. The
control group (n = 65, male 59.3%) had a mean age of
61.468.5 years at the time of index colonoscopy. There was
a statistically significant difference in age between the UC
cohort and the control group (p,0.0001). A total of 115 biopsy
sites were analysed from UC patients. Twenty four (34.8%)
subjects had a single site analysed and 45 (65.2%) had more
than one biopsy site assessed. Of the 115 biopsies analysed, 68
(59.1%) were from histologically inflamed sites, whereas 47
(40.9%) were from histologically normal sites A single biopsy
site was analysed from each control subject. The clinical
characteristics and Montreal classification of the patients with
UC are summarised in Table 1.
Detection of Campylobacter concisus from mucosal
biopsy samples of adults with UC and controls
Utilising the species-specific primers, C. concisus was detected in
23 of the 69 subjects with ulcerative colitis and 7 of the 65 controls.
The prevalence of C. concisus in the UC population was 33.3%
which was significantly higher than that in the controls, 10.8%
(p= 0.0019) (Figure 1).
Detection of all Campylobacter species from mucosal
biopsy samples of adults with UC and controls
Utilising Campylobacter genus specific primers, Campylobacter DNA
was detected in 51 of the 69 patients with UC, and 15 of the 65
controls. The prevalence of Campylobacter was significantly higher
in cases of UC, with a prevalence of 73.9% compared to 23.1% in
controls (p = 0.0001). Sequencing of the remaining Campylobacter
positive samples revealed that C. ureolyticus was present in 21.7%
(15/69) of samples from UC patients as opposed to 3.08% (2/65)
from controls (p = 0.0013) (Figure 1). Detailed breakdown of all the
species identified from both UC subjects and controls is
summarised in Table 2. Other notable members of the
Campylobacter genus that were identified include: Campylobacter
hominis, Campylobacter curvus, Campylobacter gracilis, Campylobacter
showae and Campylobacter jejuni.
Mixed Campylobacter species from mucosal biopsy
samples of adults with UC and controls
Mixed Campylobacter species were more likely in UC patients,
20.3% (14/69) as compared to controls 4.6% (3/65)
(p = 0.0084). The most commonly identified combination of
Campylobacter species in adults with UC was C.ureolyticus and C.
hominis seen in 8.7% of all cases. The most common mix in the
controls was C. concisus and C. hominis accounting for 3.1% of
cases. A variety of different Campylobacter combinations were
noted in UC as opposed to controls wherein only two
combinations involving C. concisus/C. hominis and C. hominis/C.
curvus were found (Table 2).
Prevalence of Campylobacter species and Campylobacter
concisus in relation to gender, site of disease and severity
of symptoms
There were no significant differences noted between the
prevalence of Campylobacter species or indeed C. concisus with
respect to gender of subjects with UC or controls. The prevalence
of all Campylobacter species and C. concisus with reference to extent
and severity of disease is summarised in Table 3. There were no
significant differences noted between the prevalence of Campylo-
Table 1. Clinical characteristics of subjects with Ulcerative
colitis.
Ulcerative Colitis
Number of subjects 69
Age at diagnosis(Years) ± SD 45.6627.8
Sex (Male %) 32 (46.4%)
Montreal classification (Extent)
Proctitis E1 (%) 8 (11.6%)
Left sided UC E2 (%) 44 (63.8%)
Extensive UC E3 (%) 17 (24.6%)
Montreal classification (Severity)
Clinical remission S0 (%) 7 (10.1%)
Mild UC S1 (%) 16 (23.2%)
Moderate UC S2 (%) 32 (46.4%)
Severe UC S3 (%) 14 (20.3%)
doi:10.1371/journal.pone.0021490.t001
Figure 1. Campylobacter species, Campylobacter concisus and
Campylobacter ureolyticus in subjects with ulcerative colitis and
controls. The prevalence of all Campylobacter species was 73.9% (51/
69) in subjects with UC as compared to 23.1% (15/65) in controls
(p = 0.0001). Campylobacter concisus was detected in 33.3% (23/69) of
subjects with UC, which was significantly higher than the prevalence
rate of 10.8% (7/65) from controls (p = 0.0019). Campylobacter
ureolyticus was positive in 21.7% (15/69) of samples from UC subjects
as opposed to 3.1% (2/65) in controls (p = 0.0013).
doi:10.1371/journal.pone.0021490.g001
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bacter species or specifically C. concisus with respect to extent of
disease. The detection of Campylobacter species and C. concisus was
also studied in relation to the severity of symptoms according to
the Montreal classification, as summarised in Table 3. The only
significant difference noted was with the prevalence of all
Campylobacter species and disease severity between patients with
moderate UC (87.5%) and those with severe UC (50%) (p = 0.01).
No significant differences were noted between the prevalence of
Campylobacter concisus with respect to severity of symptoms.
Prevalence of Campylobacter species and Campylobacter
concisus in relation to inflamed and non-inflamed biopsy
samples from subjects with UC
Of the 115 biopsy sites analysed from subjects with UC, 68 were
from histologically inflamed sites whereas 47 were from sites that
were histologically normal. The prevalence of all Campylobacter
species was 66.2% (45/68) from inflamed biopsies and 46.8% from
histologically normal biopsies (22/47) which was significant
(p = 0.038). However, there was no significant difference noted
between the prevalence of Campylobacter concisus in inflamed
biopsies 25% (17/68) and that from normal biopsies 21.3%(10/
47) (p = 0.64).
Comparison of Campylobacter and Helicobacter species
from mucosal biopsies
As previously stated, Helicobacteraceae PCR positivity was
significantly higher in UC than controls within this cohort: 32 of
69 (46.4%) versus 10 of 65 (15.4%) respectively (p = 0.0002) [14].
The majority of Helicobacter species were non-pylori, constituting
96.9% (31/32) of all PCR positive subjects with UC and 80% (8/
10) of all PCR positive controls. We wanted to compare the
previously published Helicobacter prevalence with Campylobacter
positivity from the current study. The prevalence of Campylobacter
in subjects with UC (51/69) was higher than the prevalence of all
Helicobacter (32/69) but it did not reach statistical significance
(p = 0.252). Similarly, the difference between the prevalence of
Campylobacter (15/65) and Helicobacter (10/65) was not statistically
significant in controls (p = 0.374). The prevalence of both these
bacterial groups was significantly less in controls as opposed to
patients with UC. Identification of mixed Helicobacter and
Campylobacter species was noted in 34.8% of all patients with UC
(24/69) and 47.1% (24/51) of the UC patients harbouring
Campylobacter.
Phylogenetic Analysis
Sequence analysis <800 bp Campylobacter genus specific PCR
amplicons, revealed a high nucleotide sequence similarity to
various Campylobacter species with a maximum identity of 99–
100%. C. concisus sequences analysed from the UC and HC group
did not cluster into separate groups in the dendogram as shown in
Figure 2.
Discussion
This study has investigated the prevalence of the Campylobacter
genus of bacteria in UC and for the first time, a positive
Table 2. Campylobacter species identified by sequencing.
Campylobacter Species
Identified







Campylobacter concisus 16 (23.2%) 5 (7.7%)
Campylobacter ureolyticus 7 (10.1%) 2 (3.1%)
Campylobacter hominis 7 (10.1%) 2 (3.1%)
Campylobacter curvus 1 (1.4%) 3 (4.6%)
Campylobacter gracilis 1 (1.4%) 0
Campylobacter showae 2 (2.9%) 0
Campylobacter jejuni 1 (1.4%) 0


























Table 3. Distribution of Campylobacter species according to extent and severity of disease.
Subjects Characteristic Number Campylobacter species Campylobacter concisus
Ulcerative colitis Montreal extent Proctitis 8 5 (62.5%) 2 (25%)
Left sided UC 44 35 (79.6%) 15 (34.1%)
Pancolitis 17 11 (64.7%) 6 (35.3%)
Montreal severity Remission 7 4 (57.1%) 2 (28.6%)
Mild 16 12 (75%) 6 (37.5%)
Moderate 32 28 (87.5%) 13 (40.6%)
Severe 14 7 (50%) 2 (14.3%)
Controls 65 15(23.1%) 7 (10.8%)
doi:10.1371/journal.pone.0021490.t003
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association has been noted between the presence of Campylobacter
species and adult UC. Campylobacter was detected in a significantly
larger proportion of UC patients as opposed to controls.
Furthermore, two individual species, namely C. concisus and C.
ureolyticus were found to have a significant association with UC.
The control group comprised of a significantly older group of
patients as they had been recruited from the bowel screening
programme. A recent study found that the greatest incidence of
Campylobacter infection was for those aged more than 60 years of
age, making this difference even more clinically significant [28]. A
study documenting prevalence of C. concisus in salivary samples
from different age groups did not find any significant difference
among various adult age groups but found the prevalence to be
significantly lower in the children age 3–5 years [29].
In the last two years, C. concisus has been associated with
paediatric CD, with two studies documenting this association from
faecal and biopsy samples [17,18]. The reported prevalence of C.
concisus from these two studies was 65% from faecal samples and
51% from biopsy samples. The prevalence of C. concisus in biopsy
samples from adult UC in our study was lower than these studies
at 31.9%. Our finding contrasts with these previous studies as it is
based on adult subjects with UC as opposed to children with CD.
Therefore, our findings have expanded the role of C. concisus to
encompass both forms of IBD necessitating further studies to firstly
validate our findings and secondly to delineate the exact
mechanism of this association.
This study not only found an increased prevalence of C. concisus
in mucosal biopsy samples from adults with UC but also identified
DNA from this putative pathogen in one in ten controls. C. concisus
is a common commensal in the oral mucosa and it has been
associated with periodontitis [30]. A study by Zhang et al aimed to
look at the relative rates of isolation and detection of C. concisus
from salivary samples of healthy controls and patients with IBD
but did not find any significant difference between the two groups
(97% vs. 100%) [29]. Protein profiling of six of the oral strains
were compared with an intestinal strain of C. concisus using SDS-
PAGE. Interestingly only one of the six oral strains matched the
intestinal strain, suggesting that different strains of the bacteria
may exist in the oral cavity with some having the ability to colonise
the intestine. The increased detection of this oral commensal in
UC may be as a result of defective innate immunity, allowing
easier access to an additional ecological niche where the organism
may potentially cause disease. This hypothesis is supported by the
detection of this pathogen during episodes of diarrhoea in
immunocompromised adults [20]. Additionally, the finding of this
bacterium in the extremes of age groups, who are characterized
with poorer immunity, suggests that C. concisus may be an
opportunistic pathogen [31].
There is an additional suggestion that C. concisus exists as a
heterogeneous population with both pathogenic and non-patho-
genic strains co-existing together, with disease being manifest
following infection with a pathogenic genotype. This has been
elegantly demonstrated by Aabenhus et al who utilized amplified
fragment length polymorphism (AFLP) analysis from a variety of
clinical isolates of C. concisus obtained from sixty-two immuno-
competent and immunocompromised individuals over a period of
five years [32]. Their analysis showed at least four distinct C.
concisus genomospecies which exhibited differences in their spectra
of virulence potential. In another similar study, analysis of SDS-
PAGE protein profiles and PCR amplification of 23S rDNA
assigned clinical C. concisus isolates into two distinct, but discordant
groups [33]. Identification of two genetically distinct clusters have
also been reported from a recent report utilizing analysis of
amplified fragment length polymorphism profiles [34]. This study
Figure 2. Phylogenetic tree constructed using sequences of the
16S rRNA gene of C. concisus strains from UC and controls and
other strains available in GenBank. Strains from UC are underlined
in red and those from HC are underlined in blue. The evolutionary
history was inferred using the Neighbor-Joining method. The bootstrap
consensus tree inferred from 500 replicates was taken to represent the
evolutionary history of the taxa analysed. The evolutionary distances
were computed using the Maximum Composite Likelihood method.
doi:10.1371/journal.pone.0021490.g002
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identified genomospecies A from healthy individuals and geno-
mospecies B from patients with diarrhoea. More importantly they
found that the pathogenic strains (genomospecies B) displayed
greater epithelial invasion and translocation. This is possibly the
first report of a genotype-phenotype correlation of pathogenicity of
C. concisus isolates. During the current study, phylogenetic analysis
was also undertaken to see if a similar clustering effect could be
seen based on 16S rDNA sequence data. Our study cohort did not
demonstrate a similar clustering effect, indicating that 16S rDNA
sequence data is not as discriminatory as 23S rDNA for
categorising C. concisus isolates. The debate on whether differing
phenotypic characteristics of C. concisus can be identified by
studying genetic composition still needs to be resolved.
In comparison to C. concisus, C. ureolyticus is a relatively unknown
gastrointestinal pathogen. In its previous nomenclature as
Bacteroides ureolyticus it was known to cause soft tissue infections
and urethritis and it has only recently been implicated as a cause of
diarrhoea [22,35,36]. Its significant association with UC in our
study suggests that these patients may be susceptible to
colonisation with Campylobacter and perhaps this is genus-specific
rather than to any particular Campylobacter species. This is
supported by the increased number of mixed Campylobacter (with
relatively rare members of the Campylobacter genus, including C.
showae, C. curvus and C. gracilis) in adults with ulcerative colitis as
opposed to controls. This finding is similar to those in paediatric
Crohn’s disease reported by Man et al [18]. The increased
diversity of Campylobacter species in UC may reflect a specific defect
in the immunological handling of this genus in the intestinal
mucosa of UC. The additional finding of mixed Helicobacteraceae
and Campylobacter species in UC suggest that this defect may extend
to the entire phylum of Proteobacteria.
A sub-group analysis of the patients with UC was performed
which found no definite relationship between extent of disease and
the prevalence of Campylobacter and specifically C. concisus. There
was a significantly lower prevalence of all Campylobacters in subjects
with severe colitis (50%) as opposed to moderate colitis (87.5%),
but no such difference was noted with the prevalence of C. concisus
infection. The obvious corollary to this finding is that our study did
not have the power to detect differences between the various sub-
groups of UC. This finding appears to be against the obvious
premise that a greater exposure should generally lead to greater
incidence of the effect. Contrary to this finding, a greater
prevalence of Campylobacter species was noted in histologically
inflamed biopsies as opposed to normal biopsy samples taken from
UC patients. One can surmise that there can be regional changes
in mucosal bacterial species, in this case Campylobacter, that may
trigger an inflammatory cascade which then leads to ulceration
and loss of the epithelial surface that harbours these organisms.
This would paradoxically lead to reduced identification of the
pathogen in the most severe phases of active disease. Future studies
should also be conducted on non-IBD inflammatory colonic
diseases to ensure that the presence of the bacteria is not merely a
superinfection of inflamed tissue.
In the classic essay by Bradford Hill on the theory of causation
he states that: ‘‘We must not be too ready to dismiss a cause and
effect hypothesis merely on the grounds that the observed
association appears to be slight’’ [37]. This doctrine is all the
more relevant when considering the role of a solitary pathogen like
C. concisus in the broader aetiopathogenesis of a multifactorial
disease like UC. The pathogenic potential of C. concisus has been
elegantly demonstrated in an in-vitro model wherein these strains
were demonstrated to be invasive and also induced production of
pro-inflammatory cytokines from epithelial cells, monocytes and
macrophages [38]. A cytolethal distending toxin (CDT)-like effect
on Vero cells has been shown by clinical isolates of C. concisus from
subjects with diarrhoea [33]. The bacterium also produces cell-
associated and secreted haemolysins that may have a role in
pathogenicity [39]. It is obvious that this bacterium can cause
tissue damage but whether it is the initiating trigger, the
perpetuating factor or merely an epiphenomenon amidst the
mucosal inflammatory cascade is a question that still needs to be
answered.
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